Does the ISCHEMIA Trial Apply to My Patients?
Vandan UpadhyayaSmitha Narayana GowdaGustavo PortoChirag P BavishiPartha SardarRiyaz BashirMustafa Emir GokceerSaurav ChatterjeePublished in: Current cardiology reports (2022)
Contemporary guideline-directed medical therapy has had a significant impact on the prognosis of coronary artery disease. Various observational data appear to indicate limited generalizability of the ISCHEMIA trial in different populations. Further studies are warranted to evaluate the optimal modality of therapy in patients with stable coronary disease and moderate or severe ischemia. The applicability of ISCHEMIA and ISCHEMIA-CKD trials still requires further validation.
Keyphrases
- coronary artery disease
- end stage renal disease
- chronic kidney disease
- study protocol
- clinical trial
- ejection fraction
- healthcare
- phase iii
- randomized controlled trial
- stem cells
- coronary artery
- phase ii
- peritoneal dialysis
- percutaneous coronary intervention
- heart failure
- early onset
- electronic health record
- machine learning
- cross sectional
- cardiovascular events
- atrial fibrillation
- aortic stenosis
- left ventricular
- patient reported outcomes
- aortic valve
- artificial intelligence
- drug induced
- data analysis